Table 3 Baseline demographic information and disease characteristics, inflammation status, therapy distribution according to histological healing status

Age, year, mean (SD)

46.71 (14.71)

51.81 (9.72)

0.067

46.82 (14.45)

50.58 (10.25)

0.230

Gender (male, %)

43 (61.43)

12 (57.14)

0.725

41 (63.08)

14 (53.85)

0.416

Hematochezia (%)

60 (85.71)

7 (33.33)

 < 0.001

55 (84.62)

12 (42.86)

 < 0.001

Disease duration of UC, years (SD)

3.70 (4.15)

7.80 (10.07)

0.082

3.64 (4.11)

7.15 (9.34)

0.076

Newly diagnosed cases (%)

10 (14.29)

1 (5.00)

0.240

8 (12.31)

3 (11.54)

0.919

Hospital stay length, days (SD)

13.55 (11.31)

6.57 (6.46)

0.008

13.89 (11.64)

7.07 (6.09)

0.006

WBC, *10^9/L, (SD)

7.86 (3.01)

5.55 (1.54)

 < 0.001

8.02 (2.99)

5.60 (1.78)

 < 0.001

Hemoglobin, g/L, (SD)

113.66 (26.63)

133.71 (16.88)

 < 0.001

113.69 (26.79)

129.77 (20.37)

0.007

Hct, %, (SD)

35.20 (7.22)

40.58 (4.28)

 < 0.001

35.22 (7.34)

39.48 (5.06)

0.002

Platelet count, *10^9/L, (SD)

313.23 (110.52)

224.52 (57.63)

 < 0.001

320.80 (111.08)

222.65 (52.09)

 < 0.001

C-reactive protein, mg/L, (SD)

38.02 (50.26)

4.51 (8.67)

 < 0.001

40.80 (51.12)

4.00 (7.88)

 < 0.001

ESR, mm/h, (SD)

23.76 (21.28)

8.57 (6.08)

 < 0.001

24.33 (21.76)

10.04 (8.01)

 < 0.001

D-dimer, µg/L, (SD)

1658.13 (3661.47)

578.53 (623.96)

0.184

1752.25 (3784.29)

550.85 (576.66)

0.015

Albumin, g/L, (SD)

36.48 (6.21)

41.00 (6.22)

0.004

36.20 (6.28)

40.81 (5.80)

0.002

Fecal Calprotectin (μg/g)

N = 43

N = 7

N = 41

N = 9

273.08 (268.56)

294.21 (434.10)

0.861

310.69 (304.19)

118.19 (153.20)

0.072

Current therapy by 5-ASA (%)

59 (84.29)

18 (85.71)

0.874

56 (86.15)

21 (80.77)

0.520

Current corticosteroids drugs (%)

10 (14.29)

1 (4.76)

0.240

9 (13.85)

2 (7.69)

0.416

Current anti-TNF treatment (%)

1 (1.43)

0 (0)

0.582

1 (1.54)

0 (0)

0.525